Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 25, 2022 at 07:21 am EDT
Share
Henan Lingrui Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 682.12 million compared to CNY 589.39 million a year ago. Revenue was CNY 682.12 million compared to CNY 589.39 million a year ago. Net income was CNY 130.77 million compared to CNY 96.58 million a year ago. Basic earnings per share from continuing operations was CNY 0.237 compared to CNY 0.17 a year ago. Diluted earnings per share from continuing operations was CNY 0.229 compared to CNY 0.17 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
HENAN LINGRUI PHARMACEUTICAL CO., LTD. 
